Alfoxil is an oral antibacterial combination consisting of amoxicillin and the beta lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).
Other names for this medication:
Alphamox,
Amixen,
Amobay,
Amocla,
Amoclan,
Amodex,
Amoklavin,
Amoksiklav,
Amorion,
Amoval,
Amoxan,
Amoxibeta,
Amoxicap,
Amoxiclav,
Amoxidal,
Amoxidin,
Amoxihexal,
Amoxiplus,
Amoxival,
Amoxsan,
Amoxy,
Amoxycare,
Ampliron,
Amylin,
Augmentin,
Augmex,
Augpen,
Bactoclav,
Betamox,
Bioclavid,
Biomox,
Blumox,
Cavumox,
Cilamox,
Clabat,
Clamentin,
Clamicil,
Clamoxin,
Claneksi,
Clavam,
Clavamel,
Clavamox,
Clavaseptin,
Clavet,
Clavipen,
Clavobay,
Clavubactin,
Clavulin,
Clavulox,
Clonamox,
Curam,
Dexyclav,
Duomox,
Enhancin,
Exten,
Fleming,
Fulgram,
Germentin,
Gimaclav,
Gloclav,
Glomox,
Hiconcil,
Himox,
Hymox,
Imadrax,
Julmentin,
Julphamox,
Kesium,
Klamoks,
Klavox,
Klavunat,
Largopen,
Macropen,
Medoclav,
Megamox,
Megapen,
Moxatag,
Moxiclav,
Moxilen,
Moxypen,
Myclav,
Mymox,
Natravox,
Neomox,
Nisamox,
Noprilam,
Noroclav,
Novaclav,
Novamox,
Novax,
Novocilin,
Optamox,
Origin,
Panklav,
Pediamox,
Pinamox,
Ranclav,
Ranmoxy,
Ranoxyl,
Rapiclav,
Ronemox,
Sulbacin,
Synulox,
Trifamox,
Unimox,
Xiclav,
Zoxil
Similar Products:
Amoxil,
Cipro,
Bactrim,
Ampicillin,
Trimox
A 14-year retrospective single-centre study of 69 consecutive paediatric patients (age 1-14 years) with appendicitis-related peritonitis and positive peritoneal specimen cultures was conducted. Post-operative outcomes, microbiology and antibiotic susceptibility of peritoneal isolates were analysed in all Cefdinir Generic Name patients.
502 children Curam 1000 Mg aged 1 month to <7 years with clinical pyelonephritis.
There is poor compliance with national (and international) guidelines for the management of AOM in this ED. National guidelines must be introduced into the department by direct teaching at senior house officer and middle grade level, a re-audit Cost Of Betamox must be carried out and regular reviews of the notes of patients diagnosed with AOM must be undertaken to ensure compliance with guidelines is maintained.
To evaluate the efficacy and safety of CLAVAMOX dry syrup (potassium clavulanate/amoxicillin) in children with otitis media, we conducted a postmarketing surveillance from February to September 2006. The analysis was made on the basis of 470 survey sheets collected from 127 medical institutions, of which we investigated 455 cases for safety, and 433 cases for efficacy. The efficacy was 95.2% in the 433 subjects eligible for the efficacy analysis. The clinical improvement rates for major symptoms ( Lupimox Capsule otalgia, otorrhea, flare reaction of drum membrane and fever) were 95% or more. The efficacies for the three major offending bacteria of otitis media (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) were between 94.6% and 100%. The efficacies for penicillin-resistant Streptococcus pneumoniae (PRSP) and penicillin intermediate resistant Streptococcus pneumoniae (PISP) were 95% or more. Adverse drug reactions (ADRs) were reported in 106 (23.3%) of the 455 subjects eligible for safety analysis. The major ADRs were diarrhea, of which incident was 22.6% (103 of 455). These ADRs were observed at a higher rate in younger age patients. Most of the diarrhea cases were non-serious, reversible on discontinuation or continuation of the drug. No clinically important serious diarrhea cases such as pseudomembranous colitis or dehydration were observed. Our surveillance results demonstrated that CLAVAMOX dry syrup had excellent efficacy and clinically manageable safety in children with otitis media. These findings indicated that this medicine was clinically-useful in children with otitis media.
Recent epidemiologic studies have demonstrated an increase of infections caused by SDSE, which will probably gain clinical relevance in the next future relatively to surgical prosthetic hernioplasty. In all cases of infection the authors suggest cultural isolation of the casual germ and the Cleocin Dose Pediatric execution of the antibiogram because the conservative medical treatment can avoid mesh removal with consequent elevated risk of hernia relapse.
The in vitro antibacterial activities of amoxycillin/clavulanate (Augmentin), ceftazidime and ceftriaxone were compared against 330 gram-negative and gram-positive strains isolated from clinical specimens received at the King Abdulaziz University Hospital (KAUH) in Saudi Arabia. The antibacterial susceptibility was determinated by Stokes method and by the minimal inhibitory concentration (MIC) using an agar dilution method. Ceftazidime and ceftriaxone were the most active antibiotics, inhibiting 90% of the tested strains by obtainable serum concentrations. Augmentin, on the other hand, had much lower activity against most of the strains tested. Ceftazidime's activity was superior to that of ceftriaxone especially against Klebsiella spp., Enterobacter spp., Supreme Toning Tower Reviews Citrobacter diversus, indole positive Proteus, Providencia stuartii, Acinetobacter calcoaceticus and Pseudomonas aeruginosa. Ceftriaxone had better activity against Serratia orderefera, Morganella morganii and Staphylococcus aureus. Beta-lactamase stable cephalosporins are therefore a potential replacement for aminoglycosides in the antimicrobial therapy of serious Gram-negative infections and alternative agents in the treatment of some Gram-positive infections.
Mechanical cardiac valve implantation was performed in 3 patients with infective endocarditis, sepsis, chronical renal insufficiency of terminal stage, to whom the programmed dialysis was conducted. The operation was performed for vital indications. All the patients after the operation are alive, their treatment was continued, using programmed hemodialysis, effect of operation is good. The success of treatment of infective endocarditis in patients with chronical renal insufficiency of terminal stage Metazol 200 Tablets depends on timely radical elimination of the infection foci in endocardium, the intracardial and systemic hemodynamics normalization, application of etiotropic antibacterial therapy, an adequate programmed hemodialysis.
Pharmacokinetic (PK) and pharmacodynamic (PD) principles that predict antimicrobial efficacy can be used to set targets for antimicrobial design and optimisation. Although current formulations of amoxicillin and amoxicillin/clavulanate have retained their efficacy against many, but not all, penicillin-nonsusceptible Streptococcus pneumoniae, additional coverage is required to address the growing problem of drug-resistant strains. Accordingly, two new oral formulations of amoxicillin/clavulanate, a paediatric formulation at 90/6.4 mg/kg/day and a pharmacokinetically enhanced formulation at 2000/125 mg twice daily for adults, were designed using PK/PD principles. These principles indicate that for amoxicillin and amoxicillin/clavulanate, a time above MIC of 35-40% of the dosing interval is predictive of high bacterial efficacy. In line with PK/PD predictions, simulation of human pharmacokinetics in in-vitro kinetic models and in a rat model of pneumonia, amoxicillin/clavulanate 2000/125 mg twice daily was highly effective against S. pneumoniae strains with Klavunat Film Tablet amoxicillin MICs of 4 or 8 mg/L. Against strains with amoxicillin MICs of 4 mg/L, amoxicillin/clavulanate 2000/125 mg twice daily was significantly more effective than the conventional 875/125 mg twice daily formulation, azithromycin and levofloxacin, even though all levofloxacin MICs were < or = 1 mg/L. Following infection with S. pneumoniae strains with amoxicillin MICs of 8 mg/L, the amoxicillin/clavulanate 2000/125 mg twice daily formulation was more effective than the conventional amoxicillin/clavulanate formulations of 875/125 mg twice daily and three times daily and 1000/125 mg three times daily, and had similar or better efficacy than azithromycin and levofloxacin, depending on the strain. These data indicate the potential benefit of therapy with amoxicillin/clavulanate 2000/125 mg twice daily compared with conventional formulations and other marketed antimicrobials in the treatment of respiratory tract infection.